| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
462.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
2,447 |
78,990 |
96,836 |
590,364 |
| Total Sell Value |
$19,013 |
$301,730 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
1 |
9 |
14 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mendlein John |
Director |
– • – |
2023-01-19 |
4 |
OE |
$1.37 |
$38,992 |
D/D |
28,461 |
311,231 |
|
- |
|
| Mendlein John |
Director |
– • – |
2023-01-13 |
4 |
B |
$5.43 |
$198,906 |
D/D |
36,631 |
282,770 |
2.39 |
-1% |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2023-01-12 |
4 |
OE |
$1.37 |
$580 |
D/D |
423 |
169,340 |
|
- |
|
| Mendlein John |
Director |
– • – |
2023-01-11 |
4 |
B |
$5.67 |
$499,232 |
D/D |
88,048 |
246,139 |
2.39 |
-9% |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2023-01-10 |
4 |
S |
$5.24 |
$57,205 |
D/D |
(10,917) |
168,917 |
|
9% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2023-01-10 |
4 |
S |
$5.24 |
$240,553 |
D/D |
(45,907) |
385,639 |
|
9% |
|
| Plavsic Mark |
Chief Technical Officer |
• – – |
2023-01-10 |
4 |
S |
$5.24 |
$17,910 |
D/D |
(3,418) |
123,705 |
|
9% |
|
| Chu Yu-Waye |
Chief Medical Officer |
• – – |
2023-01-10 |
4 |
S |
$5.24 |
$41,003 |
D/D |
(7,825) |
143,208 |
|
9% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2023-01-10 |
4 |
S |
$5.24 |
$38,414 |
D/D |
(7,331) |
129,470 |
|
9% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2023-01-10 |
4 |
S |
$5.24 |
$60,538 |
D/D |
(11,553) |
177,598 |
|
9% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2022-08-18 |
4 |
S |
$29.75 |
$153,051 |
D/D |
(5,135) |
136,801 |
|
67% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-07-22 |
4 |
AS |
$31.33 |
$200,356 |
D/D |
(6,246) |
431,546 |
|
-33% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-07-22 |
4 |
OE |
$2.70 |
$16,864 |
D/D |
6,246 |
437,792 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-07-21 |
4 |
AS |
$32.54 |
$986,361 |
D/D |
(30,000) |
431,546 |
|
-39% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-07-21 |
4 |
OE |
$2.70 |
$81,000 |
D/D |
30,000 |
461,546 |
|
- |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2022-07-07 |
4 |
AS |
$30.23 |
$518,686 |
D/D |
(17,158) |
179,834 |
|
-28% |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2022-07-07 |
4 |
OE |
$2.73 |
$46,841 |
D/D |
17,158 |
196,992 |
|
- |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2022-07-06 |
4 |
AS |
$30.07 |
$235,809 |
D/D |
(7,842) |
179,834 |
|
-23% |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2022-07-06 |
4 |
OE |
$2.73 |
$25,629 |
D/D |
7,842 |
187,676 |
|
- |
|
| Plavsic Mark |
Chief Technical Officer |
• – – |
2022-07-05 |
4 |
S |
$24.61 |
$91,525 |
D/D |
(3,719) |
127,123 |
|
21% |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2022-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
45,000 |
|
- |
|
| Epstein Robert S |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
11,331 |
|
- |
|
| Lee Michael Stewart |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
11,331 |
|
- |
|
| Coughlin Timothy P |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
9,892 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
10,659 |
|
- |
|
297 Records found
|
|
Page 2 of 12 |
|
|
0.20 (5.41%) 
